Cargando…

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival

BACKGROUND: The brain represents a frequent progression site in lung adenocarcinoma. This study was designed to analyse the association between the epidermal growth factor receptor (EGFR) mutation status and the frequency of brain metastases (BM) and survival in routine clinical practice. PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stanic, Karmen, Zwitter, Matjaz, Hitij, Nina Turnsek, Kern, Izidor, Sadikov, Aleksander, Cufer, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078036/ https://www.ncbi.nlm.nih.gov/pubmed/24991207 http://dx.doi.org/10.2478/raon-2014-0016

Ejemplares similares

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
por: Zwitter, Matjaz, et al.
Publicado: (2014)

Incorporation of EGFR Mutation Status into M Descriptor of New TNM Classification Influences Survival Curves in Non-small Cell Lung Cancer Patients
por: Stanic, Karmen, et al.
Publicado: (2019)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer
por: Bitenc, Marko, et al.
Publicado: (2022)

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
por: Koren, Ana, et al.
Publicado: (2017)

Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
por: Zwitter, Matjaz, et al.
Publicado: (2011)

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
por: Lekic, Mirko, et al.
Publicado: (2012)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival
por: Humar, Mojca, et al.
Publicado: (2017)

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
por: Sodja, Eva, et al.
Publicado: (2016)

BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma
por: Koren, Ana, et al.
Publicado: (2016)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
por: Kovac, Viljem, et al.
Publicado: (2012)

Is Postmastectomy Radiotherapy Really Needed in Breast Cancer Patients with Many Positive Axillary Lymph Nodes?
por: Marinko, Tanja, et al.
Publicado: (2018)

Independent Clinical Research May Alleviate Disparities in Cancer Treatment
por: Zwitter, Matjaz
Publicado: (2016)

Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
por: Vrankar, Martina, et al.
Publicado: (2014)

Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia
por: Stanic, Karmen, et al.
Publicado: (2023)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma
por: Shen, Tong-xu, et al.
Publicado: (2019)

Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers
por: Zhang, Huan, et al.
Publicado: (2013)

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
por: Schaller, Alexandre, et al.
Publicado: (2014)

The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status
por: Shao, Jun, et al.
Publicado: (2021)

Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status
por: Chen, Hsi-Chieh, et al.
Publicado: (2019)

Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana
por: Stanic, Karmen, et al.
Publicado: (2010)

Biology of Metastasis With Focus on Proteases
por: Cufer, Tanja
Publicado: (2005)

Glioblastoma patients in Slovenia from 1997 to 2008
por: Smrdel, Uros, et al.
Publicado: (2014)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Radiomic Signatures for Predicting EGFR Mutation Status in Lung Cancer Brain Metastases
por: Zheng, Lie, et al.
Publicado: (2022)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor
por: Smrdel, Uros, et al.
Publicado: (2016)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

Consolidation Radiotherapy for Patients with Extended Disease Small Cell Lung Cancer in a Single Tertiary Institution: Impact of Dose and Perspectives in the Era of Immunotherapy
por: Stanic, Karmen, et al.
Publicado: (2020)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6uji312edcdiu5uln9b8lv87a0